EP2805300A1 - Procédé et dispositif destinés à mesurer la pression intra-oculaire de manière continue - Google Patents

Procédé et dispositif destinés à mesurer la pression intra-oculaire de manière continue

Info

Publication number
EP2805300A1
EP2805300A1 EP13702361.0A EP13702361A EP2805300A1 EP 2805300 A1 EP2805300 A1 EP 2805300A1 EP 13702361 A EP13702361 A EP 13702361A EP 2805300 A1 EP2805300 A1 EP 2805300A1
Authority
EP
European Patent Office
Prior art keywords
data
patient
processing unit
time
medication
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13702361.0A
Other languages
German (de)
English (en)
Inventor
Max Ostermeier
Stefan Meyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Implandata Ophthalmic Products GmbH
Original Assignee
Implandata Ophthalmic Products GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Implandata Ophthalmic Products GmbH filed Critical Implandata Ophthalmic Products GmbH
Publication of EP2805300A1 publication Critical patent/EP2805300A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A61B3/16—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for measuring intraocular pressure, e.g. tonometers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4833—Assessment of subject's compliance to treatment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
    • G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Definitions

  • the present invention relates to a method and apparatus for the continuous measurement of intraocular pressure (IOP).
  • Glaucoma also called green star, refers to a variety of eye diseases of different causes, all of which have a loss of nerve fibers.
  • the most important risk factor for glaucoma is considered to be too high an IOP.
  • the time course of the IOD values is strong
  • IOP-lowering drugs are also strongly patient-dependent with regard to their general effectiveness, their latency and their duration of action. This double patient dependence often leads to an insufficient reduction of the intraocular pressure, so that far-reaching damage of the optic nerve up to the blindness of the patient despite medication are not excluded.
  • DE 10 2004 056 757 A1 has proposed an implantable, extraskleral
  • the device includes a software program accessible via the Internet, which contains a menu-driven data interpretation module. Furthermore there are access possibilities to an on-line library of reference sources.
  • a report module generates patient-specific reports for
  • a disadvantage of these known systems is that they have no
  • the method task is solved in a method for acquiring a patient's IOD time courses, comprising the steps of: a) continuously measuring and storing a patient's IOP data over a period of at least 24 hours, in his / her daily life without medication, then b) continuous measurement and storage of a patient's IOP data over a period of at least 24 hours under its medication, wherein c) a recording of medication times,
  • Medication duration duration, dosages, agents, events in the
  • the measurement of the IOD data is at least twice the frequency of an assumed time-based pattern in the IOD pressure curve and where e) a transfer of the stored data to a
  • the method according to the invention advantageously proposes a quasi-continuous measurement of the IOD course of a patient in his everyday life, wherein the method begins with the determination of a baseline IOD course without medication, which comprises at least 24 h, in order to detect the cyclical fluctuations of the pressure curve , Usually will be sufficient for about 24 hours, but is also a longer
  • Medication times, durations, dosages and the applied active substance as well as events in the course of the day of the patient can be recorded together with the measurement data.
  • This is used according to the invention to determine and quantify possible influences of the environment on the IOD course.
  • the measurement frequency follows the Nyquist-Shannonschen or the Whittaker-Kotelnikow-Shannon sampling theorem in order to minimize aliasing artifacts, ie with at least twice the frequency of an assumed time-based pattern in the IOD curve.
  • the data thus acquired are according to the invention to a
  • Processing unit passed on and evaluated there, in particular automatically evaluated, in order to increase their quality and a
  • step b) at a first time a first drug and at a second time a second drug and optionally to another
  • Step b) of the method is repeated n times, where n is the number of active substances to be tested, Drug combinations or drug doses.
  • a drug can be applied at several times or in alternation with another drug.
  • step b) two or more active ingredients are administered at a time.
  • This can also be the individual IOD history at
  • Combined active ingredients are determined.
  • the two time points of two active ingredients are significantly less than 24 h apart, so follow each other in time.
  • the subsequent administration of the active ingredient can take place, for example, after 6 h, when the effect of the previously given active substance has already subsided.
  • the evaluation of the measurement data in step e) of the method also includes the consideration of the target pressure of the patient, his personal preferences, drug tolerances, dosage levels and times, so that the treating physician a particularly well prepared and reliable in all respects and meaningful
  • the method according to the invention also includes the repetition of steps a) and b) at a time interval from the successful medical adjustment of a patient in order to provide the physician with data on the success or failure of the therapy.
  • the device for acquiring and evaluating medical data has at least one measuring device and one processing unit, the at least one measuring device having a data acquisition unit with at least one sensor, at least one data memory, at least one
  • Data transmission device and at least one operating and
  • the processing unit comprises a data transmission device and a processing unit, wherein the processing unit is applying data analysis and structure-testing statistical algorithms and filtering methods to the measurement data and wherein the processing unit comprises a display unit.
  • FIG. 1 a flow chart of the method
  • FIGS. 2a-d model IOD traces
  • Fig. 3 shows the IOD course of a follow-up examination
  • Fig. 4 is a sketchy representation of an inventive
  • Fig. 1 shows a schematic flow diagram of the method according to the invention. This begins with a baseline measurement of a patient's IOD that the patient may need to spend a few days withdrawing from their previous medication. This is followed by a recording of its IOD baseline curve over at least 24 hours.
  • the measuring frequency is 0.003Hz, ie one measurement per 5 min.
  • the measuring frequency can be higher or lower, a measuring frequency of 5 min is considered in each case according to the invention as continuous. It is to be chosen so high that the data are meaningful with respect to temporal dependencies of the IOD of influences.
  • the measurement necessarily takes place in the usual living environment of the patient and is carried out independently or started by him.
  • a sensor is used, which is implanted temporarily to the patient, for example, the sensor described in DE 10 2010 035 294 of the applicant.
  • the method can also use other sensors, such as pulse or blood pressure sensors.
  • Baseline is a first medication at a first time, whereby a new measurement cycle of at least 24h duration is started.
  • Which active substance is administered at which time in which dosage is communicated to the patient via the measuring device 1.
  • the patient carries out the appropriate instructions, with the meter reading the electronically time-stamping and saving corresponding data and times. It also stores special events with timestamps, such as physical or mental stress, meals, etc. Alternatively, the patient may also keep a non-electronic journal, but electronic data storage is preferred because of easier data availability.
  • this first effective measurement can be followed by further effective measurements, see FIG. 2a-e.
  • the data thus determined are stored in the meter and forwarded to a processing unit.
  • the processing unit generates tabular overviews that may include, for example, daily fluctuation ranges, patient compliance data (rate of the performed number of measurements, or recognizable temporal or otherwise type patterns).
  • FIGS. 2 a to 2 d show modeled IOD profiles of a method sequence with more than one medication time.
  • the representations are already such as those produced by the processing unit.
  • Fig. 2a shows a baseline IOD profile after previous elimination from a medication.
  • the abscissa is 24 hours, starting at 08:00 clock one day and ending at 08:00 clock the following day.
  • the ordinate shows the measured IOD values in [mmHg]. It turns out that this patient has high LOD values of greater than 21 mmHg, mainly at night.
  • FIG. 2 b shows an evaluation of how it can be obtained after carrying out step b) of the method, wherein the two data sets were normalized with respect to one another in terms of time.
  • a first drug A was administered at two points in time that were less than 24 hours apart, namely at a first time, 6:00 pm, in a first dose and then at a second time, 06: 00 o'clock, in a second dosage, identical to the first one, the measurement being carried out from 18:00 o'clock to 18:00 o'clock of the following day.
  • the evaluation here consisted of a time standardization of the medication IOD course to that of the baseline measurement.
  • the upper curve shows the baseline from step a), the lower curve the individual profile of action of the first drug A.
  • the two arrows indicate the two mentioned medication times. It turns out that the application of the first drug A leads to a significant reduction in IOP levels, almost throughout the day. It also shows that the reduction is insufficient to drop the IOD below 21 mmHg at night.
  • FIG. 2 c shows the evaluation of a step b) of the method in which a second drug B was administered at one time (6 pm) and the lOD courses that followed were measured over 24 h. This was done after the measurement according to FIG. 2b.
  • the evaluation was also in a time standardization, as previously described.
  • the upper curve is the baseline, the lower curve is the medication line. It turns out that there is a marked reduction in IOP over the course of the night, with the IOP dropping below 21 mmHg over the entire 24-hour period. Only in the early morning was this threshold slightly exceeded.
  • the described processes in step b) can be repeated according to the invention on consecutive or time-spaced days, for example to determine a weekly cycle of the IOD.
  • step e) is also according to FIG. 2d, in which the two, by the respective drugs in the respective
  • the ordinate shows the change of the IOD in [mmHg] compared to the baseline, the abscissa contains the time course. The latency, the duration of action and the potency of a medication are clearly visible in this evaluation.
  • FIG. 3 shows the ITEM course of a follow-up examination during a created therapy. This repetition of the invention
  • the physician receives from the evaluation a summary of the measurements in report form in the desired representations such as time series, tabular overviews, waterfall charts and the like.
  • the 4 shows a sketch of a device according to the invention. It has at least one measuring device 1, which is carried by the patient.
  • the device according to the invention is designed so that at the same time a plurality of measuring devices 1 can be operated in parallel.
  • the measuring devices 1 receive data from a sensor 4 belonging to the measuring device 1.
  • the sensor 4 is, for example, a pressure sensor, as used by the applicant, but the sensor 4 may also consist of several sensors, which in addition to the IOD also record blood pressure, heart rate or other medically relevant data and forward it to the measuring device 1.
  • the meter has a sufficiently large data memory 5 to record the measurement data of the one or more sensors 4 in sufficient time resolution over extended periods of time.
  • the measuring device 1 further has a data transmission device 6, the stored data to a
  • the data transmission device 6 is designed such that it transmits the data by wire or wirelessly, for example as a WLAN, WWan, Bluetooth, IR interface, plug-in contact, or the like.
  • the measuring device 1 further has an operating and communication interface 7.
  • the user interface is for example a screen-keyboard combination, or a touch screen, but it can also be a
  • the Communication interface is for communication between the patient and a caregiver, with the caregiver also
  • Computer program may be that appropriate instructions issued.
  • the patient shows this communication interface 7
  • the communication interface could also have a separate alarm LED, which indicates corresponding alarms visually by flashing or lights, it could also be a
  • the communication between caregiver and patient can also be done via a smartphone app or SMS, ie by means of such devices available to the patient.
  • the communication interface would be outsourced from the meter 1.
  • the communication interface also allows monitoring of the patient and cancellation of alarms with individually configurable alarm limits and alarm algorithms by the attending physician. This advantageously ensures that the individual target IOP pressure for each patient is taken into account so that no critical exceedances of IOP values occur. As a result, the number of false alarms is kept low, for example, by choosing different alarm limits of the night than during the day. Also, individual tolerable numbers of maximum pressure overshoots can be configured. According to the invention, it is also true that the alarms of the conditioning unit 2 are received by the communication interface 7, but are kept secret from the patient.
  • Alarm algorithms can be defined locally on the measuring device 1 and executed or on a central, supervising
  • the processing unit 2 may be arranged according to the invention in the meter 1 or spatially removed to this, in any case, they know a data transmission device 8 in order to receive data from the meter or devices 1 and to communicate with them. If the processing unit 2 is arranged in the measuring device 1, the individual obtained by the one or more sensors 4 are
  • Patient data can already be evaluated in the measuring instrument 1 and can be transmitted as a report to a supervising physician or read from or read from this. More advantageous, however, is the embodiment in which the processing unit 2 is arranged under operating conditions spatially separated from the measuring device 1.
  • the processing unit is 2 here
  • a local or a central database or a cloud-based program ie either one in the doctor's office
  • This processing unit 2 has a processing unit 9 and a display unit 10, the latter being, for example, a monitor.
  • the processing unit 9 has a processing unit 9 and a display unit 10, the latter being, for example, a monitor.
  • Processing unit 9 filters the data for the elimination of noise and other interfering signals, and is data analysis method and
  • Curve overlay is designed to handle problematic IOP high pressure phases in the
  • investigated algorithmically identifiable temporal course and the determined individual drug profile of action is in parameters such as latency, effectiveness, duration of action decomposing.
  • the inventive method improves the data acquisition significantly, so that the data processing is significantly improved. It is patient-specific and can be customized to its needs. This provides a doctor with meaningful data so that he can create a therapy and readjust it early if the patients' lOD patterns or their responses change.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Business, Economics & Management (AREA)
  • General Business, Economics & Management (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Eye Examination Apparatus (AREA)

Abstract

L'invention concerne un procédé lequel permet d'obtenir puis représenter l'évolution dans le temps de la PIO d'un patient pour ainsi créer une base de données optimisée portant sur l'évolution individuelle de la PIO chez un patient, et lequel comporte les étapes consistant à a) mesurer et enregistrer de manière continue les données de PIO d'un patient pendant sa vie quotidienne durant au moins 24h, sans médication, puis b) mesurer et enregistrer de manière continue les données de PIO d'un patient durant au moins 24h alors qu'il prend ses médicaments, tout en s'assurant de c) enregistrer les moments de prise de médicaments, la durée du traitement médicamenteux, les doses administrées, les principes actifs, les événements survenus dans le quotidien du patient, et de d) mesurer les données de PIO à une fréquence au moins deux fois supérieure à celle d'un schéma selon la PIO est estimée d'évoluer dans le temps, et de e) transmettre les données enregistrées à une unité de traitement puis de traiter lesdites données.
EP13702361.0A 2012-01-19 2013-01-17 Procédé et dispositif destinés à mesurer la pression intra-oculaire de manière continue Withdrawn EP2805300A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102012100441A DE102012100441A1 (de) 2012-01-19 2012-01-19 Verfahren und Vorrichtung zur kontinuierlichen Messung von Intraokulardrücken
PCT/EP2013/050797 WO2013107799A1 (fr) 2012-01-19 2013-01-17 Procédé et dispositif destinés à mesurer la pression intra-oculaire de manière continue

Publications (1)

Publication Number Publication Date
EP2805300A1 true EP2805300A1 (fr) 2014-11-26

Family

ID=47632989

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13702361.0A Withdrawn EP2805300A1 (fr) 2012-01-19 2013-01-17 Procédé et dispositif destinés à mesurer la pression intra-oculaire de manière continue

Country Status (7)

Country Link
US (1) US20140364717A1 (fr)
EP (1) EP2805300A1 (fr)
JP (1) JP5901794B2 (fr)
AU (2) AU2013211067A1 (fr)
CA (1) CA2861921A1 (fr)
DE (1) DE102012100441A1 (fr)
WO (1) WO2013107799A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2755549A1 (fr) 2011-09-13 2014-07-23 Dose Medical Corporation Capteur physiologique intra-oculaire
US9730638B2 (en) 2013-03-13 2017-08-15 Glaukos Corporation Intraocular physiological sensor
WO2016004262A1 (fr) * 2014-07-01 2016-01-07 Cao Ariel Capteurs d'implants de charge de puissance ultra-faible dotés d'une interface sans fil destinés à la surveillance d'un patient
US20170181631A1 (en) * 2014-12-03 2017-06-29 Donald Spector Multifunction biosensor system
CN114532976A (zh) 2016-05-31 2022-05-27 酷拉公司 可植入眼压传感器和使用方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06114006A (ja) * 1992-10-02 1994-04-26 Canon Inc 検査装置
US6669631B2 (en) 2000-06-14 2003-12-30 Medtronic, Inc. Deep computing applications in medical device systems
US6742895B2 (en) 2000-07-06 2004-06-01 Alan L. Robin Internet-based glaucoma diagnostic system
WO2002100260A1 (fr) * 2001-06-13 2002-12-19 Sis Ag Surgical Instrument Systems Dispositifs et procedes de determination de la pression interne d'un oeil
US20050010447A1 (en) * 2001-07-06 2005-01-13 Katsuyuki Miyasaka Patient information management apparatus and method
US20030078487A1 (en) * 2001-08-09 2003-04-24 Jeffries Robert E. Ocular pressure measuring device
US20040122294A1 (en) * 2002-12-18 2004-06-24 John Hatlestad Advanced patient management with environmental data
US20050159660A1 (en) * 2002-05-31 2005-07-21 Valentino Montegrande Intraocular pressure sensor
DE102004056757A1 (de) 2004-11-24 2006-06-01 Mesotec Gmbh Vorrichtung zur Intraokulardruckmessung
DE102006030210A1 (de) * 2006-06-30 2008-01-03 Salzsieder, Eckhard, Dipl.-Phys., Dr. rer.nat. Verfahren und Anordnung zur rechnergestützten Bestimmung des charakteristischen Tagesprofils des individuellen Glukosemetabolismus
JP2008178635A (ja) * 2007-01-26 2008-08-07 Konica Minolta Medical & Graphic Inc 咳漱解析装置
US10702174B2 (en) * 2007-06-27 2020-07-07 Integra Lifesciences Corporation Medical monitor user interface
IN2012DN03211A (fr) * 2009-09-18 2015-10-23 Orthomems Inc
DE102010035294A1 (de) 2010-08-25 2011-12-22 Implandata Ophthalmic Products Gmbh Sklera-Sensor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2013107799A1 *

Also Published As

Publication number Publication date
US20140364717A1 (en) 2014-12-11
JP2015505481A (ja) 2015-02-23
AU2016210714A1 (en) 2016-08-25
WO2013107799A1 (fr) 2013-07-25
JP5901794B2 (ja) 2016-04-13
CA2861921A1 (fr) 2013-07-25
DE102012100441A1 (de) 2013-07-25
AU2013211067A1 (en) 2014-07-24

Similar Documents

Publication Publication Date Title
DE60013828T2 (de) Gerät und verfahren zur überwachung der gewebeleitfähigkeit und verfahren zur steuerung eines warnsignals
EP0858287B1 (fr) Dispositif pour l'analyse quantitative de troubles du sommeil
Starr Auditory brain-stem responses in brain death.
DE69834664T2 (de) System zum detektieren von aufmerksamkeit und schläfrigkeit
DE60038429T2 (de) System und Verfahren zur Bestimmung einer Referenzgrundlinie eines individuellen Patientenzustands zur Benutzung in einer automatischen Sammlung und Analysesystem zur Patientenpflege
EP2887861B1 (fr) Appareil pour étudier une distribution de phases pour identifier une interaction pathologique entre différentes régions du cerveau
EP0727962B1 (fr) Procede et dispositif de detection automatique de bruits respiratoires anormaux
DE10057215B4 (de) Systeme zur Extrapolation einer Glucosekonzentration und zur Ermittlung von zu verabreichenden Insulingaben oder vorzunehmender Kohlenhydrataufnahmen
DE4091020C2 (de) Verfahren und Vorrichtung zum Überwachen, Anzeigen und/oder Aufzeichnen von bioelektrischen Spannungssignalen eines menschlichen oder tierischen Körpers
DE102007017552A1 (de) Fallabhängige Krankheitsverlaufsvorhersage bei einem Echtzeit-Überwachungssystem
EP2243423B1 (fr) Procédé et appareil de détermination de conseils pour dosages de matière active à l'aide de séries de mesures d'au moins un paramètre physiologique d'un patient
WO2013107799A1 (fr) Procédé et dispositif destinés à mesurer la pression intra-oculaire de manière continue
EP0892619B1 (fr) Appareil pour l'enregistrement de valeurs relatives a un etat de sante
EP1279416A2 (fr) Système d'analyse pour le contrôle de la reéducation
EP0633746A1 (fr) Dispositif pour diagnostique des troubles circulatoires
EP1139187A2 (fr) Méthode et dispositif de réveil
DE102008021940A1 (de) Stimulationsanordnung zur Messung der physiologischen Signalreaktivität
DE102011117573A1 (de) Verfahren und Einrichtung zum nichtinvasiven Überwachen von Schmerzstärken und zur Ermittlung von Narkosetiefen während medizinischer Eingriffe
EP1106205A2 (fr) Procédé d'opération d'un dispositif cardiaque implanté, en particulier un stimulateur cardiaque
EP3316768A1 (fr) Dispositif et procédé pour la surveillance et le diagnostic du mécanisme d'autorégulation de la pression sanguine chez un être vivant
EP1859733B1 (fr) Procédé et dispositif destinés à mettre en corrélation les signaux de respiration du système cardiocirculatoire
WO2019207130A1 (fr) Établissement d'un paramètre indiquant une perte de conscience d'un patient sous anesthésie
DE102004007169B4 (de) Verfahren und Vorrichtung zur Ermittlung einer Position zur Durchführung einer Substanzabgabe
EP2560114B1 (fr) Dispositif d'assistance d'un patient ayant une maladie chronique ou non chronique et procédé de fonctionnement du dispositif
DE102022209449A1 (de) Verfahren und Einrichtung zur Bestimmung von Bewegungsmustern einer Person

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140819

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20190920

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20210803